Ligand Announces multi-program LTP technology licensing agreement with Nucorion Pharma
Ligand announces the signing of a license agreement for three programs utilizing Ligand’s LTP (Liver Targeting Prodrug) technology with Nucorion Pharmaceuticals, a venture-funded biotechnology company focused on developing anti-cancer and anti-viral agents initially directed to China. July 29, 2016